View More Recent Stories

Oct 11, 2022 07:30AM Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease
Oct 6, 2022 07:30AM Annovis Bio Inc. (ANVS) Granted FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap
Oct 6, 2022 07:30AM Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease
Sep 29, 2022 07:30AM Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference
Sep 13, 2022 07:34AM Annovis Bio Inc. (ANVS) Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases
Sep 13, 2022 07:30AM Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases
Sep 8, 2022 07:30AM Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders
Aug 29, 2022 04:01PM Annovis Bio Inc. (ANVS) Appoints Henry Hagopian III as CFO
Aug 29, 2022 04:00PM Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer
Aug 24, 2022 07:30AM Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease
Aug 8, 2022 07:30AM Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update
Aug 1, 2022 07:30AM Annovis Bio to Participate on Alzheimer's Association International Conference Panel
Jul 14, 2022 07:30AM Annovis Bio to Present at the Alzheimer's Association International Conference
Jul 7, 2022 07:30AM Annovis Bio Inc. (ANVS) Receives Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease
Jul 7, 2022 07:30AM Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease
Jun 9, 2022 08:30AM Annovis Bio Inc. (ANVS) Submits International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections
Jun 9, 2022 08:30AM Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections
May 4, 2022 08:30AM Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
Apr 28, 2022 04:30PM Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
Apr 26, 2022 07:15AM Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors
Apr 11, 2022 08:30AM Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Mar 23, 2022 08:30AM Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Mar 18, 2022 08:30AM Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)
Mar 8, 2022 08:30AM Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022
Mar 3, 2022 08:30AM Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference
Jan 25, 2022 09:05AM Annovis Bio Inc. (ANVS) Receives Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
Jan 25, 2022 09:00AM Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
Jan 10, 2022 08:30AM Annovis Bio Enhances Leadership Team with Two Senior Appointments
Jan 5, 2022 08:30AM Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401
Jan 3, 2022 08:30AM Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences
Dec 14, 2021 08:32AM Annovis Bio Inc. (ANVS) Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Journal
Dec 14, 2021 08:29AM Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
Nov 19, 2021 08:30AM 22nd Century Group (XXII) Announces CFO Transition
Nov 19, 2021 08:30AM 22nd Century Group Announces CFO Transition
View More Recent Stories